Podcasts about semaglutide

You can listen to the first episode of this three-part series here. GLP-1 medications to treat diabetes, obesity and several other illnesses have exploded in popularity since Ozempic was approved for use in Canada back in 2018. Ozempic and Wegovy, the GLP-1s which contain semaglutide, are the third-most prescribed drug in Canada, and by far the best-selling one. Chris Hannay, The Globe's business of health reporter, will explain why the introduction of generic semaglutide will mean lower prices and more options for Canadians. And we'll explore access to these drugs with The Globe's health reporter Kelly Grant on who gets their GLP-1 covered by their insurance – and who doesn't. Plus, Globe audio producer Kasia Mychajlowycz leads us on a journey to understand just how the virtual pharmacies advertised all over her social media feed are vetting people who want Ozempic prescriptions. The next episode and final episode of Skinny, Inc. is next Monday, March 9. You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Whole food plant-based diets are safer than GLP-1 drugs and more effective than reducing meat for long-term health. #ObesitySolutions #PlantBased #WeightLoss

In the booming world of peptides, a critical and often hidden danger lurks: purity. While demand for compounds like Semaglutide and BPC-157 soars, the unregulated online market is rife with products that fail basic quality standards. This episode serves as your essential intelligence briefing, exposing the alarming truth behind research chemical websites, fabricated Certificates of Analysis (CoAs), and the shocking lack of purity in many complex peptides. Topics discussed: - Unregulated peptide market- Research chemical websites- Fabricated Certificates of Analysis (CoAs) - Independent lab findings- Simple vs. complex peptides- Contamination- Cost of purity (HPLC)---------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠My Live Program for Coaches: The Functional Nutrition and Metabolism Specialization ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.metabolismschool.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- [Free] Metabolism School 101: The Video Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.metabolismschool.com/metabolism-101⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------Subscribe to My Youtube Channel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@sammillerscience?si=s1jcR6Im4GDHbw_1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grab a Copy of My New Book - Metabolism Made Simple⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---------- Stay Connected: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: SamMillerScience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: The Nutrition Coaching Collaborative Community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok: @sammillerscience⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠----------“This Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast and the show notes or the reliance on the information provided is to be done at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for educational purposes only. Always consult your physician before beginning any exercise program and users should not disregard, or delay in obtaining, medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. By accessing this Podcast, the listener acknowledges that the entire contents and design of this Podcast, are the property of Oracle Athletic Science LLC, or used by Oracle Athletic Science LLC with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this Podcast may save and use information contained in the Podcast only for personal or other non-commercial, educational purposes. No other use, including, without limitation, reproduction, retransmission or editing, of this Podcast may be made without the prior written permission of Oracle Athletic Science LLC, which may be requested by contacting the Oracle Athletic Science LLC by email at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠operations⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@sammillerscience.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. By accessing this Podcast, the listener acknowledges that Oracle Athletic Science LLC makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast."

In this episode, we explore the groundbreaking COaST trial examining semaglutide for clozapine-induced weight gain in schizophrenia patients. Could GLP-1 agonists finally offer a real solution to one of psychiatry's most frustrating paradoxes—when the medication that saves lives simultaneously shortens them? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 78 Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial

Interview with Christian S. Hendershot, PhD, and Klara R. Klein, MD, PhD, authors of Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. Hosted by John Torous, MD. Related Content: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder Semaglutide Shows Promise in Reducing Alcohol Cravings

Interview with Christian S. Hendershot, PhD, and Klara R. Klein, MD, PhD, authors of Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. Hosted by John Torous, MD. Related Content: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder Semaglutide Shows Promise in Reducing Alcohol Cravings

In today's Daily Stock Market News (Feb 25, 2026), we cover all the major developments impacting global and Indian markets. Global markets witnessed a strong rebound, while crude oil prices surged near a 7-month high, adding to macro volatility. On the domestic front, India's GDP outlook remains resilient despite global uncertainties, and retail loan growth continues to stay strong, indicating steady credit demand.We also discuss important corporate updates including IDFC First Bank's fraud recovery developments, BKT's expansion investment plans, Voltas announcing AC price hikes, and the strategic Semaglutide partnership between Eris and Natco. Stay updated with the latest market-moving news, macro trends, and key stock-specific developments in a crisp, timestamp-based format.This video is useful for investors, traders, and anyone tracking stock market trends, economic indicators, and major corporate announcements.#stockmarketnews #dailymarketupdate #indiagdp #idfcfirstbank #globalmarkets #oilprices #RetailLoans #BKT #voltas #ErisNatco #nifty #sensex #investingindia #financenews #marketrebound 00:00 Start00:11 Global Markets Rebound02:37 Oil Near 7-Month High05:13 Retail Loan Growth Strong08:11 India GDP Outlook Resilient11:04 IDFC First Bank Fraud Recovery13:32 BKT Expansion Investment15:18 Voltas AC Price Hike17:51 Eris–Natco Semaglutide Partnership

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest on Ozempic from medical breakthroughs to real-life health impacts. Im here to unpack fresh news thats changing how we view this game-changer.A brand-new study from Rutgers University, published in the Journal of Medical Internet Research, reveals why so many stick with Ozempic despite side effects. Researchers analyzed sixty anonymous reviews on Drugs.com and found that sixty-two percent of users faced nausea, vomiting, or stomach issues, yet satisfaction soared when weight dropped. HealthDay News reports that sixty-seven percent experienced less appetite or fewer cravings for sugar and greasy foods, making the benefits outweigh the discomfort. Lead researcher Abanoub Armanious notes this cuts through social media hype to show everyday experiences: if youre losing weight, youre likely to keep going.Semaglutide, the key ingredient in Ozempic, mimics a hormone to control blood sugar, slow digestion, and curb hunger. Originally for type two diabetes, its now a weight loss powerhouse, with users seeing fifteen to twenty percent loss when paired with lifestyle tweaks, per UC Davis Health. But heres the catch: Physicians Committee research warns that stopping often leads to regaining two-thirds of the weight within a year, as the body rebounds with stronger cravings.Exciting advances are emerging. Georgia State Universitys Eric Krause found combining Ozempic-like drugs with anti-stress treatments boosts fat loss while sparing muscle and helps maintain results post-treatment. Plus, a daily oral semaglutide pill, approved this year, matches injections for thirteen to fifteen percent weight loss, according to Mount Sinai Health and the New England Journal of Medicine.Ozempic is transforming obesity care, but experts like those at UC Davis stress its best with diet, exercise, and doctor guidance to tackle root causes like stress or mental health hurdles. Note a recent retraction in the International Journal of Obesity on combo therapies, reminding us science evolves fast.Listeners, balance the wins with realities: results drive loyalty, but long-term success needs habits. Consult your doctor before starting.Thanks for tuning in, Ozempic Weightloss Unlocked listeners. Subscribe for more updates. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode, Gianna Beasley interviews Aja Beckett, the founder of Shotsy, a companion app for individuals on GLP-1 medications. Aja shares her personal journey with obesity and the challenges she faced before discovering GLP-1s. We dive into the struggles of weight management, the creation of the Shotsy app, its features, and the importance of community support. Shotsy is a mobile health tracking app specifically designed for people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Semaglutide, and Tirzepatide. It helps users monitor their injection schedule, side effects, and progress toward goals like weight loss or health improvements. Aja discusses the app's freemium model, ensuring accessibility for all users, and discusses the significance of building trust within the GLP-1 community.Download Shotsy in the App Store on Apple or Android!

Ozempic may help you lose weight—but only temporarily. Drs. Klaper and Fuhrman explain why lifestyle medicine is the true long-term solution. #OzempicMyths #LifestyleMedicine #WeightLossTruth

Okay babes… this is a very special Free The Moms episode.This one is actually a replay-style webinar training that I hosted, and I decided to bring it to the podcast because this conversation needs to happen out loud. We are talking all things peptides. Yes, GLP-1s. And also NAD+, glutathione, B12, BPC-157 and more. But the main focus of this training is GLP-1s—why so many of my clients are taking them, why some are microdosing, why some are on a full weight-loss dose… and why I personally am on a microdose.I'll be honest with you. I was nervous to release this. There is still so much stigma around GLP-1s. And I don't love that. So we're de-stigmatizing it. We're having the conversation. Because my job is to bring you information, empowerment, and options—without shame.Inside this episode, I walk you through:- What peptides actually are (and why they're not some scary foreign thing)- The difference between microdosing a GLP-1 and using a full weight-loss dose- Why I chose to microdose—and how I think about it in the context of longevity and metabolic health- Semaglutide vs tirzepatide (single agonist vs dual agonist) and what that actually means- What my clients are experiencing on these medications- Side effects like nausea and how they're managing it- Why medical oversight matters and how to think about doing this responsiblyWe also talk about other supportive peptides like NAD+ and glutathione, and why this conversation is bigger than “just weight loss.” For many of my clients, this is about metabolic healing, inflammation, energy, and feeling like themselves again.If you're curious, skeptical, interested, or just want to understand what the heck everyone is talking about, this episode is for you. You get to decide what's right for your body. Always.If you want to explore further, you can check out the peptides portal here:https://lmd.com/LauraConleyAnd if you attended the webinar live (or signed up), you'll receive the replay, consult link, booking link, and all resources via email.I love you guys. I'm proud of you for being open-minded. And I'm committed to giving you the tools and information you need to make empowered choices for your health. Hosted on Acast. See acast.com/privacy for more information.

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

At Complete Midlife Wellness Center, many women ask us if there is a GLP-1 option that doesn't involve injections. In this video, I walk you through what truly matters: ✅ How oral absorption differs from injections. ✅ Why injectable GLP-1 medications are often more effective — and sometimes more affordable. ✅ Who is a good candidate for oral therapy, and who will likely need something stronger.

Dhruv Khullar, practicing physician, associate professor of health policy and economics at Weill Cornell Medical College and contributing writer at The New Yorker, talks about the effect GLP-1 drugs, like Ozempic, are having on curbing addictions and what researchers are studying about that phenomenon.Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images

Part 2 picks up right where Part 1 ends—and goes deeper into what people are really wondering: What's safe? What's real? And who can I trust? Jamie and Jaclyn  talk about how misinformation spreads, why some people experience negative outcomes (often by skipping proper dosing, labs, and provider follow-ups), and why these wellness tools are most powerful when used with structure and medical guidance. You'll also hear a transformation story that's bigger than weight—one that changed energy, marriage, medications, and an entire family's trajectory. This episode is a reminder that the first step isn't dramatic… it's brave. www.YourHealth.Org

Join us as we review and appraise recent practice-changing articles on oral semaglutide for obesity, fish oil in ESRD, IV iron during infection, the new US Dietary Guidelines, & anticoagulation after ablation in AFib. Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Rahul Ganatra (@rbganatra), Josh Gilman, & Matt Watto (@doctorwatto).Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMECredits Written and Hosted by: Rahul Ganatra MD, MPH; Paul Williams, MD, FACP, Joshua Gilman, MD, & Matthew Watto MD, FACP Cover Art: Rahul Ganatra, MD MPH Reviewer: Emi Okamoto, MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer Oral Semaglutide for obesity Fish Oil for CV risk reduction in hemodialysis patients IV Iron for iron deficiency anemia during infection New USA Dietary Guidelines Anticoagulation after catheter ablation for AF Outro Sponsor: FIGSCheck out the limited-edition Team USA collection, and get 15 percent off your first order at Wearfigs.com with code FIGSRX. Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.  Sponsor: GustoTry Gusto today at gusto.com/CURB, and get three months free when you run your first payroll.Sponsor: MDProgress For our listeners, enjoy your first month free at mdprogress.ca/promo/curbsiders

Hear from the co-editors-in-chief of Osteoarthritis and Cartilage journal on what they thought were the latest advances in osteoarthritis research in 2025.Anne-Marie Malfait, MD, PhD, is Professor of Medicine and the Klaus E. Kuettner, Chair of Osteoarthritis Research at Rush University. She is co-Editor-in-Chief of Osteoarthritis and Cartilage journal alongside David Hunter.RESOURCESDavid's papers Comparative efficacy and safety of exercise modalities in knee osteoarthritis: systematic review and network meta-analysis Clinical and cost-effectiveness of a cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and ObesityAnne-Marie's paperFM-dye inhibition of Piezo2 relieves mechanically evoked pain in mouse models of acute inflammatory and osteoarthritic knee painAssociation of Synovial Innate Immune Exhaustion With Worse Pain in Knee OsteoarthritisLipidomics unravels lipid changes in osteoarthritis articular cartilageCONNECT WITH USJoin one of our trials https://www.osteoarthritisresearch.com.au/current-trialsInstagram: @ProfDavidHunterTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news and updates on Ozempic, from its medical uses to its effects on lifestyle and health.Ozempic, containing semaglutide, mimics a natural hormone called GLP-1 to release insulin, steady blood sugar, slow digestion, and curb appetite, helping listeners feel full longer. GoodRx reports that studies show people on Ozempic lose six to seven percent of body weight, while Wegovy users average fifteen percent.Recent Cochrane reviews commissioned by the World Health Organization, released February eleventh, twenty twenty-six, confirm GLP-1 drugs like Ozempic deliver meaningful weight loss. Semaglutide leads to about eleven percent reduction after six to seventeen months, with benefits lasting up to two years if continued. Tirzepatide in Mounjaro and Zepbound shows even higher losses around sixteen percent, though more research is needed. Liraglutide offers four to five percent loss.Real-world evidence from Applied Clinical Trials highlights heterogeneous results, typically four to twelve percent loss at six to twelve months. For a twelve percent drop, the drug accounts for sixty-three percent, with context like persistence, lifestyle, and care making up thirty-seven percent. Improving persistence could boost outcomes further.Many hit an Ozempic plateau after twelve months, per GoodRx. Factors include dose, timing, diet, exercise, stress, and other meds like sulfonylureas or antidepressants. Pair it with avoiding fried foods, high-fat items, sugary drinks, and ultra-processed foods for best results.Rutgers Health research in the Journal of Medical Internet Research finds sixty-seven percent of users report weight loss or less appetite despite side effects like nausea, prioritizing effectiveness to keep going. However, stopping leads to regain, though half maintain some loss after a year.Watch for Ozempic face, gauntness from facial fat loss, as noted in a PMC study, so discuss screening and diet with doctors.These updates show Ozempic transforms lives when combined with healthy habits, but long-term independent data is key.Thank you listeners for tuning in. Subscribe for more insights. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commissioned by the World Health Organization analyzed GLP-1 drugs including semaglutide, sold as Ozempic and Wegovy. These studies, drawing from dozens of trials with tens of thousands of participants, show semaglutide leads to an average weight loss of about 11 percent after six to 18 months when paired with diet and exercise. Tirzepatide, marketed as Mounjaro and Zepbound, achieved around 16 percent loss in similar periods. Researchers note these benefits persist during treatment but emphasize limited long-term safety data, common side effects like nausea, and heavy industry funding in most trials. Cochrane reports highlight the need for independent studies on heart health, quality of life, and global access, as high costs limit use in lower-income regions.A Rutgers Health study published this week in the Journal of Medical Internet Research examined why Ozempic users stick with it despite side effects. Analyzing online reviews, researchers found perceived effectiveness in curbing appetite and shedding pounds outweighs issues like stomach upset for most. Lead author Abanoub Armanious noted that everyday users prioritize real results over hype from celebrities or social media. Separately, Weill Cornell Medicine researchers reported on February 11 that GLP-1 drugs like tirzepatide may lower risks of diabetic retinopathy progression in diabetes patients, countering earlier concerns.Oprah Winfrey continues to speak openly about her GLP-1 use, as covered in recent AOL articles. The media icon, who lost about 50 pounds starting in 2023 but regained 20 after briefly stopping, now views these medications as a lifelong tool like blood pressure drugs. Promoting her book Enough, Winfrey shared on The View and her podcast that the drugs silenced constant food thoughts, freeing her from self-blame. She told listeners obesity is not a willpower failure but a brain-driven condition, urging others to seek medical options without shame. Winfrey, who covers costs for friends, also noted reduced alcohol cravings as a bonus.Meanwhile, excitement builds around Eli Lillys oral pill orforglipron, an injectable-free alternative to Ozempic. Phase 3 trials like ATTAIN-1 showed 12.4 percent average weight loss over 72 weeks, with many maintaining results after switching from shots. Walk In reports it could launch in Canada soon, offering daily convenience without fasting, though generics of semaglutide arrive mid-2026 for affordability.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Episode 212: Managing HFpEFHyo Mun and Jordan Redden (medical students) explain how to manage HFpEF with medications and touch some basics about nonpharmacologic treatments. Dr. Arreaza asks insightful questions to guide the discussion. Written by Hyo Mun, MSIV, American University of the Caribbean; and Jordan Redden, MSIV, Ross University School of Medicine. Comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Treatment of HFpEFArreaza: Mike, if you had to name the one therapy everyone with HFpEF should be on, what is it?Mike: That's easy! SGLT-2 inhibitors. This is the one slam-dunk we have in HFpEF. Empagliflozin (Jardiance) or dapagliflozin (Farxiga) should be started in essentially every patient with HFpEF, and it doesn't matter if they have diabetes or not.Jordan: And that's worth repeating, because people still think of these as “diabetes drugs.” They're not anymore. In HFpEF, SGLT-2 inhibitors reduce heart-failure hospitalizations, improve symptoms, improve quality of life, and even reduce cardiovascular death.Dr. Arreaza: They're also simple. Empagliflozin 10 mg daily or dapagliflozin 10 mg daily. No titration, no drama. The effectiveness of these meds was established around 2019 with DAPA-HF and later with DELIVER. These were trials thatdemonstrated that dapagliflozin reduces worsening heart failure and cardiovascular events across the full spectrum of heart failure, from reduced to preserved ejection fraction, independent of diabetes status.Mike: And the number needed to treat is about 28 to prevent one heart-failure hospitalization. That's excellent for a disease where we historically had almost nothing that worked.Jordan: They're also safe in chronic kidney disease down to an eGFR of about 25, which makes them even more useful in this population.Dr. Arreaza: Alright. We got SGLT-2 inhibitor, what's next?Mike: Volume management. Loop diuretics are still the backbone of symptom control in HFpEF. If the patient is volume overloaded, you diurese, and you diurese aggressively.Jordan: The goal is euvolemia. Dry weight, no edema, no orthopnea, no waking up gasping for air. A lot of these patients end up needing chronic oral loop diuretics to stay there.Dr. Arreaza: Something to remember: HFpEF patients don't tolerate congestion well, and being “a little wet” is not benign. Let's move into RAAS inhibition. Where do ARBs and ACE inhibitors fit in?Mike: Between ARBs and ACE inhibitors, ARBs are the winners in HFpEF. They actually reduce heart failure hospitalizations—drugs like candesartan, losartan, valsartan. ACE inhibitors? Not so much. They showed minimal benefit in older HFpEF patients, which is why we go with ARBs instead.Jordan: But a lot of clinicians get nervous about ACE inhibitors and ARBs because of kidney function, so it's worth talking through how these drugs actually work in the kidney.Dr. Arreaza: Yes, misunderstanding may lead to unnecessary drug discontinuation.Jordan: Under normal conditions, the afferent arteriole brings blood into the glomerulus, and the efferent arteriole is constricted by angiotensin II. That constriction keeps pressure high in the glomerulus and maintains filtration.Mike: Here's what happens with an ACE inhibitor: you block angiotensin II, the efferent arteriole relaxes, glomerular pressure drops, and GFR dips slightly. Creatinine bumps up a little, and that scares people, but that's actually the whole point—that's how you get kidney protection long-term.Jordan: High intraglomerular pressure causes hyperfiltration injury and scarring over time. Lowering that pressure protects the kidney long-term. The short-term GFR drop is the price you pay for long-term benefits.Dr. Arreaza: So let's talk about CKD, because this is where people panic.Mike: Right. ACE inhibitors and ARBs are not contraindicated in chronic kidney disease. In fact, they're recommended even in advanced stages. They reduce progression to kidney failure by about a third.Jordan: The key is how you use them. Start low. Check creatinine and potassium one to two weeks after starting, then periodically. A creatinine rise up to 30% from baseline is acceptable. That's not kidney injury, that's physiology.Dr. Arreaza: And what about potassium creeping up?Mike: You adjust the dose or add a potassium binder. You don't just automatically stop the drug.Dr. Arreaza: Now there is one absolute contraindication everyone needs to know about! (board exam test)Jordan: Bilateral renal artery stenosis. This is the big one. In these patients, the kidneys are completely dependent on angiotensin II–mediated efferent constriction to maintain GFR. Take that away, and GFR collapses.Mike: Creatinine can jump dramatically within days. If you see a creatinine rise of 20% or more shortly after starting an ACE inhibitor, you should be thinking about bilateral renal artery stenosis and stopping the drug immediately.Dr. Arreaza: After revascularization, though, many patients can tolerate ACE inhibitors again, so this isn't always permanent. What about cardiorenal syndrome? That's where things get uncomfortable.Mike: It is uncomfortable, but cardiorenal syndrome isn't a contraindication. These patients have severe heart failure and kidney disease, and their mortality is actually higher than patients with heart failure alone.Jordan: ACE inhibitors still reduce mortality and slow kidney disease progression in this group. Studies show that stopping ACE inhibitors during acute heart-failure admissions increases in-hospital mortality three- to four-fold.Dr. Arreaza: So we are cautious, but we don't avoid it.Mike: Exactly. Start low, titrate slowly, monitor labs closely, accept up to a 30% creatinine rise. You only stop if kidney function keeps worsening, or potassium gets dangerously high.Dr. Arreaza: Alright. Let's move on. What about mineralocorticoid receptor antagonists… MRA?Jordan: Spironolactone or eplerenone might reduce hospitalizations in HFpEF, but the data is mixed. This is more of a “select patients” situation.Mike: And you have to watch potassium and kidney function carefully, especially if they're already on an ACE inhibitor or ARB.Dr. Arreaza: What about sacubitril-valsartan, also known as Entresto®?Mike: Entresto may help patients with mildly reduced EF roughly in the 45 to 57% range. It's not first-line for HFpEF, but in select patients, it's reasonable.Dr. Arreaza: Now let's clarify one of the biggest sources of confusion: beta blockers.Jordan: Beta blockers are not a treatment for HFpEF itself. They're only indicated if the patient has another reason to be on them, like coronary disease or atrial fibrillation.Mike: And timing really matters here. You absolutely do not start beta blockers during acute decompensated heart failure. Their negative inotropic effects can make things worse when patients are volume overloaded.Jordan: But, and this is critical, you also don't stop them if the patient is already taking one. Abrupt withdrawal causes a sympathetic surge and dramatically increases mortality.Dr. Arreaza: If a patient is admitted on a beta blocker, what do we do?Mike: Continue it at the same dose or reduce it slightly if they're really unstable. Once they're euvolemic and stable, you can carefully titrate up.Jordan: And watch for chronotropic incompetence. HFpEF patients often rely on heart-rate response to exercise, and beta blockers can worsen exercise intolerance.Dr. Arreaza: Beyond medications, HFpEF is really about treating comorbidities. Aerobic activity can be an initial strategy to improve exercise intolerance and has evidence of improving aerobic function and quality of life. Sodium restriction: improves symptoms, does not decrease risk of death or hospitalizations.Mike: Hypertension control is huge. For diabetes, the SGLT-2 inhibitors will perform double duty. For obesity, weight loss improves symptoms, and GLP-1 agonists like semaglutide are absolute gamechangers.Jordan: Don't forget sleep apnea, atrial fibrillation, and lifestyle. Exercise improves the quality of life, even if it doesn't change hard outcomes. Lifestyle is the main treatment. Dr. Arreaza: And when should you refer to cardiology?Mike: You should refer when the diagnosis isn't clear; symptoms are not responding to treatment, difficult volume management, end-organ dysfunction, or if you are concerned about advanced heart failure.Dr. Arreaza: So, it has been a great discussion. What is the takeaway?Mike: HFpEF treatment isn't about one magic drug -- it's about volume control, SGLT2 inhibitors, smart use of RAAS blockade, and aggressive management of comorbidities.Jordan: And it's understanding the physiology, so you don't withhold life-saving therapies out of fear.Dr. Arreaza: Well said. If you found this helpful, share it with a friend or colleague and rate us wherever you listen. This is Dr. Arreaza, signing off.Jordan/Mike: Thanks! Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Barzin A, Barnhouse KK, Kane SF. Heart Failure With Preserved Ejection Fraction. Am Fam Physician. 2025;112(4):435-440.Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895-e1032.Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023;81(18):1835-1878.Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098.Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392.Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. Lancet. 2003;362(9386):777-781.Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620.Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084.Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19. JAMA Cardiol. 2020;5(11):1265-1273.Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury. Eur Heart J. 2020;41(39):3827-3835.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.Badve SV, Roberts MA, Hawley CM, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in adults with estimated GFR less than 60 mL/min per 1.73 m². Ann Intern Med. 2024;177(8):953-963.Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney: a risk-benefit assessment. Drug Saf. 1996;15(3):200-211.Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med. 1985;102(3):308-314.Hackam DG, Spence JD, Garg AX, Textor SC. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007;50(6):998-1003.Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539.Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure. JACC Heart Fail. 2015;3(8):647-653.Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-2192.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide.  This special episode is sponsored with support from Novo Nordisk. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health W. Timothy Garvey, MD.,  Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. Selected references: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al.  N Engl J Med 2023;389:2221-2232  

Why are most Americans struggling with weight gain, obesity, and the serious health problems that follow? Dr. Hotze explains how being overweight has become one of the most widespread health issues in the United States, contributing to diabetes, heart disease, fatty liver disease, high blood pressure, and more. He explores why these numbers have risen so dramatically over the past several decades and why this trend is largely unique to America. Dr. Hotze discusses two major drivers behind weight gain: a slowed metabolism due to impaired thyroid function and the overconsumption of processed, high-carbohydrate foods. He explains how fluoride exposure can interfere with thyroid hormone activation, reducing metabolism and energy production, while excess sugar and simple carbohydrates drive insulin resistance and fat storage. The conversation also addresses the growing use of GLP-1 medications, such as Semaglutide, outlining how they work, why they produce rapid weight loss, and the potential risks associated with muscle loss, digestive complications, and long-term health consequences. This episode emphasizes that lasting weight loss is not achieved through quick fixes or expensive medications, but through sustainable lifestyle changes. Dr. Hotze shares real-life success stories and explains how adopting a clean, whole-food eating plan, restoring metabolic balance, and committing to long-term habits can lead to profound improvements in health, energy, and vitality. The message is clear: taking charge of your health naturally can transform not only your weight, but your overall quality of life. For more information about the Body Reboot Program, visit BodyRebootChallenge.com. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/   Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old.  Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best!   https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live..  the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other.  I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to  identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks.  XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA.   The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA.   The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein.   https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update.     Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors.   https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this..   I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes.  Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience.  They're also launching the MiniMed 780G system Pump Evaluation Program.  This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance.  This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX   https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6.  The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.

In this episode, we sit down with Sarah Kennedy, Founder and CEO of Calocurb, to explore a radically different approach to appetite control rooted in real science, not willpower. With decades of leadership in nutrition and food science, Sarah breaks down how GLP-1s work, the downsides of chronic calorie restriction, and the key differences between synthetic drugs like semaglutide and natural GLP-1 stimulation. We dive into the history of bitters, digestion, and how Calocurb's patented ingredient Amarasate® supports appetite regulation through the gut–brain axis. Sarah also shares compelling clinical trial results, insights on coming off GLP-1 drugs, and why under-eating—especially for women—can backfire hormonally. It's a nuanced, empowering conversation about working with your biology to feel satisfied, nourished, and in control.Founder and CEO of Calocurb, Sarah Kennedy shepherded years of scientific research and clinical trials to bring a revolutionary product to market. A veterinarian by training, with more than 20 years' experience in dietary and animal nutrition, Sarah has held a number of CEO and senior executive positions in food and agriculture industries, at companies including Fonterra and Healtheries/Vitaco NZ.  In 2010, at MIT, Sarah completed a Sloan Fellowship Program in Global Leadership and Innovation and has spent decades leading in health, nutrition and consumer products with executive roles at many, many companies.Calocurb is a 100% natural appetite control supplement. Amarasate®, the patented active ingredient in Calocurb, was developed in New Zealand over 14 years and with $30m invested by Plant and Food Research, the largest NZ government-owned research institute.SHOW NOTES:0:40 Welcome to the show!2:39 About Sarah Kennedy3:54 Welcome her to the podcast!5:04 What is a GLP-1?7:27 Downside of calorie restriction8:52 Natural vs synthetic GLP-113:41 Coming off of GLP-1s14:56 Why it isn't just willpower18:07 History of bitters in the diet20:12 Stimulating digestion & appetite suppression23:22 Calocurb Study26:02 Semaglutide vs Calocurb29:45 Clinical trial results32:54 Calocurb & PMS34:10 Dosing Calocurb40:08 Our personal experiences43:37 Importance of protein intake46:41 Females that are under-eating54:52 Where to find Sarah & Calocurb55:30 Her final piece of advice57:21 Thanks for tuning in!RESOURCES:Website: www.Calocurb.com - Discount code: BIOHACKERBABESIG: CalocurbFacebook: CalocurbGLOBALSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

#ElGranMusical | Francisca Cifuentes. Semaglutide ¿Es recomendado para bajar de peso? by FM Mundo 98.1

Cuales son los paises latinoamericanos mas infieles del mundo?

Episode 211: Understanding HFpEF.  Hyo Mun and Jordan Redden (medical students) explain the pathophysiology of heart failure with preserved ejection fraction (HFpEF) and how it differentiates from HFrEF. Dr. Arreaza asks insightful questions and summarizes some key elements of HFpEF. Written by Hyo Mun, MS4, American University of the Caribbean; and Jordan Redden, MS4, Ross University School of Medicine. Comments and edits by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.What is EF? Just imagine, the heart is a pump, blood gets into the heart through the veins, the ventricles fill up and then squeeze the blood out. So, the percent of blood that is pumped out is the EF. Let's start at the beginning. What is HFpEF?Mike: HFpEF stands for heart failure with preserved ejection fraction. Basically, these patients squeeze normally—their ejection fraction is 50% or higher—but here's the thing: the heart can't relax and fill the way it should. The muscle gets stiff, almost like a thick leather boot that just won't stretch. And because the ventricle can't fill properly, pressure starts backing up into the lungs and the rest of the body. That's when patients start experiencing shortness of breath, leg swelling, fatigue—all those classic symptoms.Dr. Arreaza: And this is where people get fooled by the ejection fraction.Mike: Exactly. The ejectionfraction tells you total left ventricular emptying, not just forward flow.Jordan: The classic example is severe mitral regurgitation. You can eject 60% of your blood volume and still be in cardiogenic shock because most of that blood is leaking backward into the left atrium instead of going into the aorta. So, you get pulmonary edema, hypotension, fatigue, all with a “normal” EF. Which is honestly terrifying if you're over-relying on echo reports without thinking clinically.Dr. Arreaza: And in HFpEF, functional mitral regurgitation often shows up later in the disease. It's not usually the primary cause; it's more of a marker of advanced disease. Moderate to severe MR in HFpEF independently predicts worse outcomes, including a higher risk of mortality or heart failure hospitalization. So, let's contrast this with HFrEF. How are these two different?Mike: HFrEF—heart failure with reduced ejection fraction—is a pumping problem. The heart muscle is weak and can't contracteffectively. Ejection fraction drops below 40%, and this is your classic systolic dysfunction.Jordan: HFpEF, on the other hand, is diastolic dysfunction. The heart muscle is thick, fibrotic, and noncompliant. It squeezes fine, but it just doesn't relax, even though the EF looks reassuring on paper.Mike: I like to explain it this way: HFrEF is a weak heart that can't squeeze. HFpEF is a stiff heart that can't relax. Totally different problems.Dr. Arreaza: And then there's the gray zone: heart failure with mildly reduced EF, or HFmrEF. That's an EF between 41 and 49% with evidence of elevated filling pressures. It really shares the features of both worlds. So, what actually causes HFpEF versus HFrEF?Jordan: HFpEF is basically what happens when all the problems of modern living catch up with you. You've got chronic hypertension, obesity, diabetes, metabolic syndrome, aging, systemic inflammation—all of these things slowly remodel the heart over years. The muscle gets thick and stiff, and eventually the ventricle just loses its ability to relax. So, HFpEF is really a disease of metabolic dysfunction and chronic stress in the heart. Mike: HFrEF is more about direct injury. Think about myocardial infarctions, ischemic cardiomyopathy, viral myocarditis, alcohol toxicity, chemotherapy like doxorubicin, genetic cardiomyopathies, or chronic uncontrolled tachycardia. These insults actually damage or kill heart muscle cells, leading to a dilated, weak ventricle that can't pump effectively.Dr. Arreaza: So the short version: HFpEF is caused by chronic metabolic and hypertensive stress, while HFrEF is caused mainly by myocardial damage. A question we get a lot: does HFpEF eventually turn into HFrEF? What do you guys think?Mike: In most cases, no. HFpEF patients usually stay HFpEF throughout their disease course. They don't just “burn out” and turn into HFrEF.Jordan: They're generally separate disease entities with different pathophysiology. A patient with HFpEF can develop HFrEF if they have a big myocardial infarction or ongoing ischemia that damages the muscle, but that's not the natural progression.Mike: Interestingly though, the opposite can happen. Some HFrEF patients actually improve their ejection fraction with good medical therapy—that's called HF with improved EF—and it's a great sign that treatment is working.Dr. Arreaza: Another question. How do HFpEF and HFrEF compare to restrictive cardiomyopathy and constrictive pericarditis?Jordan: Clinically, they can all look very similar: dyspnea, edema, fatigue, but the underlying mechanisms are completely different.Mike: In HFpEF, the myocardium itself is stiff from hypertrophy and fibrosis. The problem is intrinsic to the heart muscle, and EF stays preserved. Echoshows diastolic dysfunction with elevated filling pressures.Jordan: In HFrEF, the myocardium is weak. The ventricle is often dilated and contracts poorly, with a reduced EF.Mike: Restrictive cardiomyopathy is different. Here, the myocardium gets infiltrated by abnormal stuff—amyloid, iron, sarcoid—and that makes it extremely stiff. It can look like HFpEF on the surface, but it's usually more severe. On Echo You'll see biatrial enlargement, small ventricles, and preserved EF. And importantly, it's a pathologic diagnosis, so you need advanced imaging or biopsy to confirm it.Jordan: Constrictive pericarditis is another mimic, but here the myocardium is usually normal. The problem is that the pericardium is thickened, calcified, and rigid. This will physically prevent the heart from being filled. Imaging shows pericardial thickening, septal bounce, and respiratory variation in flow, and cath shows equalization of diastolic pressures, which is the hallmark of constrictive pericarditis.Dr. Arreaza: So the takeaway is: HFpEF is a clinical syndrome driven by common metabolic and hypertensive causes, while restrictive and constrictive diseases are specific pathologic entities. If “HFpEF” is unusually severe or not responding to treatment, you need to think beyond HFpEF. Which type of heart failure is more common right now?Mike: Good question, the answer is: HFpEF. It now accounts for up to 60% of all heart failure cases, and it's still rising.Dr. Arreaza: Why is that?Jordan: Because people are living longer, gaining weight, and developing more metabolic syndrome. HFpEF thrives in older, or people with obesity, hypertension, or diabetes: basically, the modern American population. At the same time, better treatment of acute MIs means fewer people are developing HFrEF from massive heart attacks.Mike: HFpEF is the heart failure epidemic of the 21st century. It's honestly the cardiology equivalent of type 2 diabetes.Dr. Arreaza: Let's talk aboutCOVID-19. (2025 and still talking about it) Does it actually increase heart failure risk?Mike: Yes, absolutely. COVID increases both acute and long-term heart failure risk.Jordan: During acute infection, COVID can cause myocarditis, trigger massive inflammation, and precipitate acute decompensated heart failure, especially in patients with pre-existing disease. It also causes microthrombi, which can injure the myocardium.Mike: And after infection, even mild cases are linked to a significantly higher risk of developing new heart failure within the following year. Both HFpEF and HFrEF rates go up.Dr. Arreaza: I remember seeing this in 2021, we had a patient with acute COVID and HFrEF, her EF was about 10%, I lost contact with the patient and at the end I don't know what happened to her. What's the pathophysiology of COVID and heart failure?Mike: COVID causes direct viral injury through ACE2 receptors, triggers massive inflammation that damages the endothelium and heart muscle, leads to microvascular clotting and fibrosis—all mechanisms that promote HFpEF.Jordan: Add autonomic dysfunction, persistent low-grade inflammation, and worsening metabolic syndrome, and you've got a perfect storm for heart failure.Dr. Arreaza: Bottom line: COVID is a cardiovascular disease as much as a respiratory one. If someone had COVID and now has unexplained dyspnea or fatigue, think about heart failure. Get an echo, get a BNP, start treatment. Last big question: why did we have so many therapies for HFrEF but essentially none for HFpEF for years?Mike: HFrEF is mechanistically straightforward. You've got a weak heart with excessive neurohormonal activation going on — so you block RAAS, block the sympathetic system, drop the afterload. The drugs make sense.Jordan: HFpEF is messy. It's not one disease. It's stiffness, fibrosis, inflammation, microvascular dysfunction, metabolic disease, atrial fibrillation, all overlapping. One drug can't fix all of that.Mike: And some drugs that worked beautifully in HFrEF actually made HFpEF worse. Take Beta blockers, for example.  They slow heart rate, which is a problem because HFpEF patients rely on heart rate to maintain their cardiac output.Jordan: The breakthrough came with SGLT-2 inhibitors: diabetes drugs that unexpectedly addressed multiple HFpEF mechanisms at once: volume, metabolism, inflammation, and myocardial energetics.Dr. Arreaza: The miracle drug for HFpEF! Alright, let's wrap up.Mike: Bottom line: HFpEF is common, complex, and dangerous: even if the EF looks “normal.”Jordan: And if you're relying on ejection fraction alone, HFpEF will humble you every time.Dr. Arreaza: If you liked this episode, share it with a friend or a colleague and rate us wherever you listen. This is Dr. Arreaza, signing off.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Barzin A, Barnhouse KK, Kane SF. Heart Failure With Preserved Ejection Fraction. Am Fam Physician. 2025;112(4):435-440.Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895-e1032.Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction. J Am Coll Cardiol. 2023;81(18):1835-1878.Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098.Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392.Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. Lancet. 2003;362(9386):777-781.Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-1620.Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084.Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19. JAMA Cardiol. 2020;5(11):1265-1273.Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury. Eur Heart J. 2020;41(39):3827-3835.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.Badve SV, Roberts MA, Hawley CM, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in adults with estimated GFR less than 60 mL/min per 1.73 m². Ann Intern Med. 2024;177(8):953-963.Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney: a risk-benefit assessment. Drug Saf. 1996;15(3):200-211.Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med. 1985;102(3):308-314.Hackam DG, Spence JD, Garg AX, Textor SC. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007;50(6):998-1003.Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539.Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure. JACC Heart Fail. 2015;3(8):647-653.Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-2192.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

Oprah Winfrey has been candid this week about her ongoing use of GLP-1 medications like those containing semaglutide, the active ingredient in Ozempic, for weight management. In recent interviews promoting her new book Enough: Your Health, Your Weight, and What It's Like to be Free, co-authored with Yale professor Dr. Ania M. Jastreboff, she shared that she started these weekly injections in 2023 and views them as a lifelong tool, much like blood pressure medicine. Oprah told People magazine she feels no shame in relying on them, explaining that after stopping for six months to test her willpower, she regained 20 pounds despite strict dieting and exercise. She now believes obesity influences overeating through genetics and hormones, freeing her from self-blame after decades of public scrutiny and jokes about her weight.Social media buzzed with debate over her comments on The View, where she said obesity causes overeating rather than the reverse, a view some experts clarify starts with overeating leading to obesity, which then complicates appetite control via elevated hunger hormones. Still, Oprah emphasizes these drugs help by reducing hunger and slowing stomach emptying, as noted by Harvard Health.Meanwhile, regulators issued fresh guidance on GLP-1s this week. The UK's Medicines and Healthcare products Regulatory Agency updated advice for prescribers and patients on semaglutide products like Ozempic and Wegovy, highlighting a small risk of severe acute pancreatitis. They noted about 1.6 million adults in England, Wales, and Scotland used these for weight loss between early 2024 and early 2025, per University College London research. In Canada, generic semaglutide became possible after Novo Nordisk's data exclusivity expired on January 4, promising more affordable options soon.Long-term data reinforces their efficacy. The STEP 5 trial showed once-weekly semaglutide yielding 15.2 percent sustained weight loss at 104 weeks, with mild gastrointestinal side effects like nausea most common. Tirzepatide, a dual agonist, outperformed in the SURMOUNT trials with up to 25 percent loss over 88 weeks. Experts like Dr. Caroline Apovian from Harvard stress indefinite use for best results, alongside diet and exercise, while new oral versions and pipeline drugs like amycretin aim to improve access.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

If you've started a GLP-1 medication and found yourself thinking, "Why am I so tired all of a sudden?", you're definitely not alone. Today, we're talking specifically about fatigue with semaglutide and tirzepatide—what the research actually shows, why fatigue seems more common with some GLP-1s than others, and what you can do if your energy feels lower than usual. Read the Full Episode Transcript: https://pepties.com/fatigue-on-semaglutide-or-tirzepatide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Purchase Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

This issue will review: 1.     Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial 2.     Impact of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: Results from the SOUL Randomized Trial 3.     The effect of substituting water for artificially sweetened beverages on glycemic and weight measures in people with type 2 diabetes: The Study of Drinks with Artificial Sweeteners (SODAS), a randomized trial 4.     Effects of carbohydrate-restricted diets and macronutrient replacements on cardiovascular health and body composition in adults: a meta-analysis of randomized trials Trial Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Could medications originally designed for diabetes actually help treat addiction, eating disorders, and the biology of cravings?In this part 2 of 2-part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to dig deeper into the science, myths, and emerging uses of GLP-1 agonists. Dr. Wharton explains that these medications don't simply reduce appetite, they calm what he calls “food noise,” the constant mental pull toward eating that many people with obesity experience. This neurological effect has opened the door to exciting possibilities: early research suggests GLP-1 drugs may also reduce cravings for alcohol and other addictive behaviors.  Dr. Wharton also clarifies the confusing world of brand names. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are tirzepatide. The differences are largely about FDA indications and insurance coverage, not completely different medications.The episode tackles common fears patients and clinicians hear every day. Do these medications cause eating disorders? No, in fact, they may help treat them. Are the side effects dangerous? Usually not, and most are manageable with proper dosing. Is “Ozempic face” real? It's simply normal fat loss, not a drug-specific problem. Most importantly, Dr. Wharton reinforces a compassionate, evidence-based message: obesity is a chronic, biological disease, and GLP-1 medications are tools to treat it, just like medications for blood pressure or diabetes.Three Actionable TakeawaysGLP-1 Medications Affect the Brain as Much as the Stomach: These drugs reduce “food noise” and cravings, helping patients regain control over eating behaviors. Their impact is neurological, not simply about willpower or restriction.Side Effects Are Real—but Usually Manageable: Nausea, constipation, and GI symptoms are the most common issues, especially early on. Starting low and increasing doses slowly makes treatment far more tolerable.Treatment Decisions Should Be Individualized:  Not every patient must stay on these medications forever. Conversations about duration, goals, and expectations should be collaborative and tailored to each person.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Healthspan Podcast, Dr. Robert Todd Hurst, MD, FACC, FASE, assembles a powerhouse panel to discuss what actually yields results in reversing cardiometabolic disease and why most healthcare models fall short. He's joined by Healthspan strategist coaches Claire, Christina, and Rielyn, along with guest researcher Amarei Bandy, who reveals never-before-seen data from her thesis on the real-world impact of coaching and lifestyle medicine. They dive deep into the science, stories, and strategy that make HealthspanMD's approach radically more effective than conventional care, and reveal insights that could transform your health, no matter your starting point.   ⏱ Time Stamps Time Topic 00:00 Why heart disease is mostly preventable, and how HealthspanMD is different 02:15 Introducing Omari's research and HealthspanMD coaches 04:30 How coaching impacted weight, labs, and outcomes 06:50 GLP-1 + coaching vs GLP-1 alone, shocking data revealed 11:40 What makes Healthspan coaching different from others 16:15 The secret to results: clarity, consistency, and single-point focus 18:00 Why “your why” drives everything 23:00 Building trust, partnerships, and personalized support 30:00 Why mindset makes habit change easier than you think 34:50 Reversing insulin resistance, patient stories and tactics 46:00 The power of small wins: intermittent fasting, glucose tracking, and more 52:00 Dr. Hurst's mission: No one should ever die of a heart attack   This information is for educational purposes only and is not medical advice. Don't make any decisions about your medical treatment without first talking to your doctor.   *Connect* *with* *HealthspanMD* :

You've probably heard of GLP-1 drugs like semaglutide and tirzepatide—and maybe you've even wondered, “Should I be on one of these?” This conversation is my honest, compassionate take on these powerful weight loss medications: not medical advice, not fear-mongering, and definitely not hype.In this episode, I unpack what GLP-1 receptor agonists (a class of anorectic drugs) really are, how they work, why they're so effective for fat loss—and what most people don't realize about what happens when you stop taking them. I'll walk through recent research, potential side effects, and the rebound weight gain that happens to so many… not because you failed, but because of basic human physiology.This is a supportive conversation for anyone who's considering these medications, already using them, or just wants to better understand their role in the weight loss space. And while there's no shame in using tools like these, lifestyle change still has to be the foundation. Always.What we go over:What GLP-1 drugs actually do in your bodyWhat happens after you stop taking them (and why)Why muscle loss and metabolic slowdown are often overlookedThe importance of strength training, protein, and movement—even with medsWhy long-term success still comes down to habits, not just prescriptionsHow to think critically and compassionately about weight loss toolsThese drugs are effective—but they're not magic. Let's have the real conversation.Sources:Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarenghi R. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. Journal of Clinical Medicine. 2025; 14(11):3791. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized StudiesSun Q. (2026). Weight regain after cessation of GLP-1 drugs. BMJ (Clinical research ed.), 392, r2586. https://doi.org/10.1136/bmj.r2586West S, Scragg J, Aveyard P, Oke J L, Willis L, Haffner S J P et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis BMJ 2026; 392 :e085304 doi:10.1136/bmj-2025-085304Support the showGet Weekly Health Tips: thrivehealthcoachllc.com Join the Thrive Collective Facebook group Let's Connect:@‌ashleythrivehealthcoach or via email: ashley@thrivehealthcoachingllc.com Podcast Produced by Virtually You!

Please share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nyle00:00:00 - Intro00:02:40 - Podcast Start00:03:00 - Turkey Hair Transplant00:04:50 - Quitting Finasteride00:09:18 - Skull Needles & Anesthesia00:11:46 - Piercings Gone Wrong00:14:26 - Nipple Piercings00:17:15 - Meeting Melissa00:21:00 - 12 Weeks Out?00:24:11 - 90s Hardcore vs. Science00:32:10 - Digestion First00:37:00 - Off-Season Insulin Strategy00:40:48 - Gaining 15lbs in 3 Weeks00:42:37 - No More Chicken00:46:12 - Eating Raw Testicles00:49:04 - Fruit & Digestion00:50:48 - High Volume Training00:56:23 - How My Calves Died01:02:00 - Best Body Part01:05:49 - Vacuum & Gut Control01:08:00 - Career PED Dosages01:13:00 - GH & Insulin Timing01:16:48 - Insulin & Digestion01:19:00 - Current Cycle (300 Test)01:20:56 - Feeling Small (Deflated)01:24:46 - The IVF Journey01:27:10 - Gender Selection Laws01:28:22 - Daily Micro-Injections01:29:58 - The PMMA Scandal01:33:07 - No AIs Needed01:35:18 - Deca vs. Masteron01:37:05 - Why Masteron Now?01:38:52 - Aromatization Genetics01:41:47 - Future Cycle Plans01:47:55 - The 99ng/dL Crash01:53:23 - Peptides for Repair01:55:35 - Retatrutide for Bulking?02:01:11 - GHK-Cu for Skin02:02:40 - The White Fish Diet02:07:54 - Hybrid Training is a Trap02:09:30 - The Mindset of Peeled02:14:00 - Finding Your Volume Limit02:18:20 - The McDonald's Rebound02:22:11 - Marriage & Prep02:27:13 - The Greg Doucette Beef02:29:11 - Fertility on Gear02:32:30 - Patrick Tuor Era02:37:34 - Coaching CBum02:41:28 - 2024 Olympia Placings02:42:16 - The Smoking Video02:44:20 - Advice for Young Blasters02:46:06 - The "Trauma Pro"02:48:44 - Final Message

Most people think they go into your body and make all new tissue… but in actuality, they are a delivery mechanism of growth factors. I call them the ultimate traffic cop. In this episode, the host converses with Dr. Jesse Morse, a physician specializing in regenerative and anti-aging medicine. They delve into the intricacies of stem cells and their various sources, including bone marrow, fat, and donor tissue.  Dr. Morse highlights the role of exosomes and growth factors in the healing process. The discussion also focuses on the prevention and treatment of Achilles tendon tears, emphasizing the importance of blood supply, proper diagnosis, and innovative therapies. Additionally, they explore the benefits and applications of various peptides, including BPC 157, TB 500, and MotC, for enhancing healing, anti-aging, and overall health. Dr. Morse also addresses the significance of nutrition and detoxification in maintaining optimal health and preventing injuries. Dr. Jesse Morse is a Miami-based, double board-certified physician in Family and Sports Medicine who specializes in regenerative medicine, injury recovery, and longevity. Since shifting from traditional sports medicine in 2020, he has focused on non-surgical approaches to tendon and ligament injuries using therapies like PRP, stem-cell–based treatments, exosomes, and peptides, alongside functional and anti-aging strategies centered on mitochondrial health, immune support, toxin reduction, and personalized recovery—helping everyone from active adults to high-performance athletes restore function and prevent major injuries like Achilles tears while educating widely online. Connect with him on: Instagram: https://www.instagram.com/drjessemorse/ — Sports medicine, regenerative medicine & insights Linktree (aggregated links to socials & resources): https://linktr.ee/DrJesseMorse   Supplements, Compounds & Peptides Collagen (protein / connective tissue support): https://www.ncbi.nlm.nih.gov/books/NBK507922/ Vitamin C (collagen activation / antioxidant): https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ Creatine (muscle & mitochondrial support): https://ods.od.nih.gov/factsheets/Creatine-HealthProfessional/ BPC-157 (peptide – tendon & gut healing): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504390/ TB-500 / Thymosin Beta-4 (peptide – tissue repair): https://pubmed.ncbi.nlm.nih.gov/22674782/ GHK-Cu (copper peptide – skin, joints, stem-cell signaling): https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu MOTS-c (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/25174616/ SS-31 / Elamipretide (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/29515116/ Thymosin Alpha-1 (immune modulation peptide): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367996/ LL-37 (antimicrobial / immune peptide): https://pubmed.ncbi.nlm.nih.gov/15184378/ 5-Amino-1MQ (NNMT inhibitor / fat loss): https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1MQ N-Acetylcysteine (NAC – liver & detox support): https://www.ncbi.nlm.nih.gov/books/NBK537183/ Glutathione (antioxidant / detox): https://ods.od.nih.gov/factsheets/Glutathione-HealthProfessional/ NAD⁺ / NMN / NR (mitochondrial & anti-aging support): NMN: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-mononucleotide NR: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-riboside Regenerative & Injection Therapies PRP – Platelet-Rich Plasma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990861/ Bone Marrow–Derived Stem Cells (BMAC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630382/ Adipose-Derived Stem Cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416130/ Amniotic / Placental Tissue Products: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124018/ Exosomes (cell signaling vesicles): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465611/ Ultrasound-Guided Injections: https://radiopaedia.org/articles/musculoskeletal-ultrasound-guided-injection Needle Tenotomy (scar-tissue disruption): https://pubmed.ncbi.nlm.nih.gov/30428129/ Detox, Blood & Environmental Interventions Sauna (heat detox & cardiovascular benefit): https://www.health.harvard.edu/staying-healthy/saunas-and-your-health Binders – Modified Citrus Pectin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452227/ GI Detox / Toxin Binders (general concept): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654245/ Heavy Metal Chelation (DMPS concept): https://pubmed.ncbi.nlm.nih.gov/12198644/ Mercury Toxicity: https://www.cdc.gov/mercury/index.html Microplastics in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068600/ EBOO Therapy (ozone-based blood filtration): https://pubmed.ncbi.nlm.nih.gov/36681461/ Therapeutic Plasma Exchange (TPE): https://www.ncbi.nlm.nih.gov/books/NBK557561/ INUSpheresis (advanced plasma filtration): https://pubmed.ncbi.nlm.nih.gov/37324197/ Medications & Drug Classes Mentioned Corticosteroids (Prednisone – tendon risk): https://medlineplus.gov/druginfo/meds/a601102.html Fluoroquinolone Antibiotics (tendon rupture risk): https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-fluoroquinolone-antibiotics GLP-1 Agonists (Semaglutide / Tirzepatide / Retatrutide discussion): Semaglutide: https://pubmed.ncbi.nlm.nih.gov/36421543/ Tirzepatide: https://pubmed.ncbi.nlm.nih.gov/35220624/ Nutrition & Food-Related Mentions Protein Intake & Muscle Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566799/ American Gluten vs European Wheat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799814/ Seed Oils & Inflammation (discussion topic): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196963/ Dairy & Inflammation (contextual mention): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122229/ Key Mechanisms & Concepts Poor Blood Supply in Achilles Tendon (Watershed Zone): https://pubmed.ncbi.nlm.nih.gov/17021202/ Mitochondrial Dysfunction & Aging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843959/ Stem Cells as "Medicinal Signaling Cells": https://pubmed.ncbi.nlm.nih.gov/25784997/   Show Notes 00:00 Introduction to Exosomes and Stem Cells 01:01 Dr. Morse's Background and Transition to Regenerative Medicine 02:03 Achilles Tendon Tears: Causes and Prevention 05:02 Preventative Measures and Treatments for Achilles Injuries 10:26 The Role of Nutrition in Tendon Health 12:53 Peptides and Their Impact on Tendon Health 15:50 Stem Cells: Misconceptions and Applications 20:52 Comparing Stem Cell Sources and Their Potency 29:52 The Controversy of International Stem Cell Treatments 34:04 Cleaning Toxins from Your Blood 34:19 The Toxic Burden in Our Environment 35:57 Practical Detox Methods 37:47 Mercury and Heavy Metal Testing 44:47 The Problem with American Gluten 46:49 Underrated Peptides for Health 53:42 Growth Hormone and Anti-Aging 01:03:34 Advanced Blood Cleaning Techniques 01:04:51 Conclusion and Contact Information   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Are GLP-1 medications truly revolutionizing medicine—or are we just seeing the latest healthcare hype cycle?In this part 1 of 2- part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to explore the real story behind GLP-1 agonists, how they were discovered, how they work, and why they suddenly became cultural blockbusters. Dr. Wharton explains that while the public sees these drugs as new, clinicians in diabetes care have been using them for over a decade. Originally developed to treat type 2 diabetes, GLP-1 medications revealed an unexpected benefit: meaningful weight loss. What began as a “sleeper drug” for glucose control became a global phenomenon once their impact on appetite and cravings was understood.A major theme of the discussion is the concept of “food noise”—the relentless mental pull toward food that many patients experience. Dr. Wharton describes how this biological drive makes long-term weight loss extraordinarily difficult and why willpower alone is rarely enough. GLP-1 medications work by quieting this food noise, helping patients regain control over their eating behaviors.The conversation also tackles tough questions clinicians and patients ask every day:Why do people need to stay on these medications long-term? Why do patients with diabetes lose less weight than those without? Is obesity truly a disease, and how should doctors talk about it? Are the benefits due to the drug itself or simply the weight loss? Dr. Wharton breaks down the biology of GLP-1 hormones, their role in insulin regulation and appetite control, and why these drugs have been such rare “unicorns” in medicine, highly effective with relatively few side effects.This episode sets the stage for Part 2, where they will dive deeper into myths, side effects, and practical prescribing guidance.Three Actionable TakeawaysObesity Is a Biological Disease, Not a Willpower Problem: Food noise and cravings are driven by hormones and brain chemistry. GLP-1 medications treat these biological mechanisms, not a character flaw.Long-Term Treatment Is Often Necessary: Just like medications for blood pressure or cholesterol, GLP-1 drugs address a chronic condition. Stopping treatment usually means the underlying biology—and weight—returns.Language Matters in Patient Care: Clinicians should approach weight with empathy and humility. Inviting patients into a respectful conversation about options is far more effective than blaming or shaming.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Centor discusses the comparative risk for severe gastrointestinal adverse events associated with dulaglutide, semaglutide, and tirzepatide with Dr. Wajd Alkabbani.

Please share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nyleTimestamps:00:00:00 - Intro00:03:19 Father Steve00:05:28 Banned on Social Media00:07:45 Raving00:12:06 Harm Reduction for Partying00:13:36 Alcohol Toxicity & "Cocaethylene"00:15:25 The Ultimate Hangover Stack00:18:54 Injectable Glutathione & NAC00:23:00 Rave Fashion: Cyclops Shades00:24:34 The Lifestyle Cutting Stack (TRT + GLP-1)00:26:58 The Crackdown on Peptides00:27:53 Cagrilintide Nightmares00:29:29 Orlistat & "Oily" Disasters00:31:36 Peptides for Naturals?00:33:57 The Sting of GHK-Cu00:35:23 Injectable Winstrol00:36:16 YK-11 vs. Superdrol00:39:21 Follistatin: Hype or Real?00:43:04 Mitochondrial Health Stack00:46:24 When to Start TRT?00:47:30 Adding Primo or Masteron00:50:36 My Tequila Mistake00:51:14 My Full Health Protocol00:53:11 What NOT to Take at Parties00:59:11 GHB vs. Alcohol01:00:00 High-Dose Melatonin01:02:17 Competitive Prep Stacks01:06:21 Nyle's Contest Cycle Revealed01:07:24 The "Pharmacy" Load01:13:38 Protecting the Brain (Neuroprotection)01:16:54 Epitalon & Longevity01:20:12 SGLT2 Inhibitors ("Biker Flows")01:21:15 Methylene Blue & Serotonin Syndrome01:24:42 Nootropics: Alpha GPC & Choline01:27:00 Noopept & Bromantane01:30:03 Tanner's Aston Martin01:34:55 Chinese Generics & Heavy Metals01:38:14 1000ng/dL Naturally?01:44:06 Underrated Meds (Telmisartan)01:46:24 Managing Cholesterol01:50:41 Equipoise Anxiety & Kidneys01:56:53 Hair Loss Prevention02:04:33 The "Femboy" Aesthetic Trend02:07:33 Future Drugs (Retatrutide)02:20:58 GLP-1s Saving Marriages02:23:18 Training Volume in Prep02:24:53 Low Iron in Bodybuilders02:27:12 Top 3 Steroids Ranked02:28:55 Substitutes for Primo/Mast02:30:52 Best Beginner Cycle02:34:44 Conceiving on Cycle02:38:16 Post-Cycle Muscle Retention02:41:40 Steve's Ladyboy Story02:50:49 NPP & Neurotoxicity02:52:10 Closing Wisdom

Today we're diving into how medications like semaglutide, tirzepatide, and retatrutide work in the body—and how they compare to the hormones your body naturally produces. Once you understand the biology behind them, their effects start to make a lot more sense. Read the Full Episode Transcript: https://pepties.com/the-science-behind-semaglutide-tirzepatide-and-retatrutide/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Purchase Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

If you're a midlife woman who feels like you're doing everything right — lifting weights, eating well, walking, managing stress — and your body still isn't responding, this episode is for you.In this powerful, myth-busting conversation, I'm joined by Dr. Rocio Salas-Whalen, a triple board-certified endocrinologist, obesity medicine specialist, author, and early adopter of GLP-1 therapies in the U.S. Dr. Salas-Whalen helps us understand why weight gain in midlife is not a willpower problem — it's a biology problem.We break down:Why midlife metabolism changes so dramatically during perimenopause and menopauseHow GLP-1 medications actually work (in plain English)Why muscle is the true organ of longevity — and how to protect it while using GLP-1sThe truth about side effects like hair loss, nausea, and “Ozempic face”Microdosing vs. full dosing, long-term use, and what's coming next in obesity medicineWhy shame-based weight loss advice is outdated — and harmfulWe also talk about Dr. Salas-Whalen's new book, Weightless, a science-backed, compassionate guide to GLP-1 medications and metabolic health that validates what so many women have experienced for decades. You can find Weightless wherever books are sold.This episode is about options, not pressure. Facts, not fear. And building health for the long game.Instagram https://www.instagram.com/drsalaswhalen/Website https://www.nyendocrinology.com/_________________________________________1:1 health and nutrition coaching or Faster Way - Reach me anytime at mailto:mfolanfasterway@gmail.com If you're doing “all the right things” and still feel stuck, it may be time to look deeper. I've partnered with EllieMD, a trusted telehealth platform offering modern solutions for women in midlife—including micro-dosed GLP-1 peptide therapy—to support metabolic health and longevity. https://elliemd.com/michelefolan - Create a free account to view all products. ✨ Sign up for my weekly newsletter: https://michelefolanfasterway.myflodesk.com/i6i44jw4fq

I am thrilled to have Dr. Ken Berry joining me on the podcast for the third time today. He was with me before on episodes 111 and 139. Dr. Berry is a physician, best-selling author, and passionate health advocate with a no-nonsense approach to health and wellness. He has been practicing at the Berry Clinics since 2003 and is an active community member. He has written two books, Lies My Doctor Told Me and the recently published Kicking Ass After Fifty, in addition to various other resources, including Common Sense Labs Today. He also has a YouTube channel, serving over 2 million subscribers- one of my favorite go-to resources for my patients.  In our conversation today, we dive into the latest Lancet research on the impact of a diabetes diagnosis on life expectancy, along with insights from the American Diabetes Association regarding the costs of diabetes care. We discuss the need for proper diagnostic modalities to identify insulin resistance earlier and the labs Dr. Berry uses in his practice for identifying those at risk. We explore the recently recognized American Heart Association syndrome, CKM (Cardiovascular Kidney Metabolic Syndrome), and the role of GLP agonists, continuous glucose monitors, and glucometers. Dr. Berry also shares his views on plant-based diets, proper diets, and more.  IN THIS EPISODE YOU WILL LEARN: Why does metabolic health continue to deteriorate in most of the general population?  The staggering amount of disposable plastic used within the healthcare industry The importance of fasting insulin levels when diagnosing metabolic disease Why are blood tests essential for determining metabolic health? The benefits of glucometers and continuous glucose monitors for metabolic health How Dr. Berry's health improved after following a specific diet and measuring his lab results for a month How misinformation gets spread within the health and wellness industry Why are doctors not informing their patients about the absence of long-term studies and deluding them with false information? The long-term effects of Semaglutide on the body  How a proper diet can naturally lower lipid levels The limitations of the germ model for treating chronic diseases  Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community (The Midlife Pause/Cynthia Thurlow)  Cynthia's Menopause Gut Book is on presale now! Cynthia's Intermittent Fasting Transformation Book The Midlife Pause supplement line Connect with Dr. Ken Berry On ⁠YouTube⁠ ⁠Instagram⁠, ⁠Facebook⁠ ⁠Twitter⁠ Dr. Berry's books ⁠Lies My Doctor Told Me⁠  ⁠Kicking Ass After 50⁠    ⁠Common Sense Labs⁠  Dr. Berry's Private Community ⁠Phdhealth.community⁠ Medical News article Mentioned ⁠Here's What to Know About Cardiovascular-Kidney-Metabolic Syndrome, Newly Defined by the AHA ⁠  Previous Episodes Featuring Dr. Ken Berry ⁠Ep. 111 – Is The Keto Diet The Proper Human Diet? – with Dr. Ken Berry⁠ ⁠Ep. 139 – Hyperinsulinemia: What You Should Know About This National Health Crisis with Dr. Ken Berry

Renaissance Periodization: Training on gear vs. natty, how training styles affect the look of one's physique, slow vs fast twitch training, intensifiers & myoreps, peptides, the future of PED's, & myostatin inhibitors. The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com00:00:00 The Red Skin Phenotype00:01:25 Trensparent Origins00:03:23 Visual Diagnostics00:07:23 The Roundness Myth00:10:47 Vibes vs. Physiology00:15:46 The Failure Paradox00:18:15 Volume Kings00:22:23 The Thailand Spirit00:25:16 Genetic Determinism00:30:30 The Volume Response00:36:03 The DUP Protocol00:38:44 Glass Cannons00:43:42 The Recovery Trap00:51:37 Tech-Enhanced Gains00:54:00 Intensifier Logic01:04:02 Weed & Gains01:09:00 The Booty Clap Test01:10:12 The God Stack01:16:18 Exercise Mimetics01:18:04 The Post-Steroid Era01:24:12 The Final Message

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down two GLP-1 studies that challenge a major media myth: GLP-1 medications don't drive weight loss just because people eat less. Instead, drugs like tirzepatide and semaglutide create direct metabolic shifts—including increased fat oxidation and improved fuel partitioning—regardless of appetite.The team also explores mechanical eating, the psychological impact of “diet food,” and Andrea's 13-year metabolic recovery journey.Key Questions AnsweredIf both groups are dieting, why does the tirzepatide group lose more weight?What is metabolic adaptation, and why does dieting slow metabolism so sharply?How do GLP-1s directly increase fat oxidation?What is mechanical eating, and why do GLP-1 users need it?Why does ad-lib eating produce different metabolic responses than calorie restriction?Can mindset alone change hunger hormones? (Yes—the milkshake study.)Why do diet foods and diet sodas fail to improve metabolic health?Why is response to GLP-1s so different from person to person?Key TakeawaysGLP-1s are metabolic drugs—not appetite suppressants.Their power comes from hormonal effects on fat burning, not reduced food intake.Calorie restriction still slows metabolism.Even on GLP-1s, dieting triggers significant metabolic slowdown.Ad-lib eating outperforms dieting in the research.Semaglutide users who ate freely did not show the extra metabolic slowdown seen in dieters.Mechanical eating is the most durable long-term approach.Regular meals and snacks protect lean mass and prevent famine signaling.Mindset shapes hormones.Believing a food is “diet” vs. “indulgent” alters ghrelin and satisfaction.Track body composition—not just the scale.DEXA scans show whether you're losing fat, muscle, or bone.Dr. Cooper's Actionable TipsDon't diet on GLP-1s. Focus on fueling, not restriction.Use mechanical eating: predictable meals and snacks, no long gaps.Prioritize satisfaction: diet foods often backfire hormonally.Follow your real-world data: long-term changes matter more than short-term scale shifts.Ask about body composition testing if possible.Notable Quote:“What that study proved is that doing the calorie restriction is causing the metabolic slowing… and that's why it's so confusing to me that we keep advising people to restrict calories when they're trying to improve their metabolic function.” —Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Question: questions@fatsciencepodcast.comDr. Cooper Email: dr.c@fatsciencepodcast.comFat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational only, and is not intended to be medical advice.

Broadcast from KSQD, Santa Cruz on 1-08-2026: Dr. Dawn concludes her 2025 medical advances recap, noting that while GLP-1 weight loss drugs showed unexpected benefits for addiction, schizophrenia, and dementia risk, Novo Nordisk recently reported semaglutide had no effect on cognition in people with existing dementia or mild cognitive impairment. She describes the first successful human bladder transplant performed on May 4th. The 41-year-old recipient received both kidney and bladder due to the bladder's complex blood vessel network. Surgeons practiced on cadavers with active circulation before achieving success, opening pathways for future bladder-only transplants for the 84,000 Americans diagnosed with bladder cancer annually. An emailer follows up about purslane for cognitive health. Dr. Dawn reviewed the referenced studies and found neither actually supported claims about purslane and cognition—one discussed the Lyon Heart Study's Mediterranean diet, the other described antioxidant properties. She cautions listeners that websites citing "scientifically proven" claims often reference articles that don't support their assertions. An emailer asks about statin alternatives after developing severe muscle pain on both atorvastatin and rosuvastatin. Dr. Dawn suggests he shouldn't be on statins given his classic adverse reaction. She recommends ezetimibe plus oat bran for cholesterol, metformin for his elevated triglycerides indicating insulin resistance, and checking LDL particle size and inflammation markers. She emphasizes that cholesterol is a risk factor, not a disease, and treating 50 low-risk people for 10 years prevents only one heart attack. A caller discusses plaque formation theory, comparing it to calluses. Dr. Dawn explains Linus Pauling's similar hypothesis that plaque forms at vessel bifurcations to protect against turbulent blood flow damage. She warns against driving total cholesterol below 130, as it disrupts steroid hormone production. The caller shares his mother's near-fatal rhabdomyolysis from statins—muscle breakdown releasing myoglobin that clogs kidneys—and criticizes data transfer failures between hospital systems. An emailer reports four UTIs in two months at age 79. Dr. Dawn questions whether all were true infections, since vaginal contamination causes false positives on dipstick tests. For confirmed UTIs, she recommends D-mannose and cranberry to prevent bacterial adhesion, post-void residual ultrasound to check for incomplete emptying, lactobacillus probiotics, and vaginal DHEA (Intrarosa) to restore mucosal thickness and disease resistance. Dr. Dawn describes Stanford's Phase III trial for dystrophic epidermolysis bullosa, where defective collagen-7 causes skin layers to separate at the slightest touch. Researchers take patient skin biopsies, use retroviruses to insert corrected genes, grow credit-card-sized skin grafts over 25 days, then suture them onto wounds. At 48 weeks, 65% of treated wounds fully healed versus 7% of controls. She reports a Stanford study showing premature babies who heard recordings of their mothers reading for 2 hours 40 minutes daily developed more mature white matter in language pathways. The left arcuate fasciculus showed greater development than controls, demonstrating how early auditory stimulation shapes brain circuitry even in NICU settings. Dr. Dawn concludes with tattoo safety concerns. Modern vivid inks contain compounds developed for car paint and printer toner, including azo dyes that break down into carcinogenic aromatic amines—especially during laser removal. Pigment particles migrate to lymph nodes and persist in macrophages, causing prolonged inflammation. She advises those with tattoos to avoid laser removal, wear sunscreen, practice lymphatic hygiene, and reconsider extensive new tattoos.

Midlife weight gain, burnout, and metabolic changes often get mislabeled as willpower issues. This episode challenges the oversimplified weight loss narrative and unpacks why many women feel blindsided by changes even when their habits stay solid.We dive deeper into this in the Broads episode with Dr. Tyna Moore. We also chat about why GLP-1 was never meant to be a vanity weight loss tool, why microdosing doesn't mean what most people think it means, and the real risks of frailty and why strength equals long-term freedom.Dr. Tyna Moore is a Licensed Naturopathic Physician and Chiropractor with over 30 years in the medical field, specializing in holistic regenerative and metabolic medicine. She earned her degrees from the National College of Natural Medicine and the University of Western States Chiropractic College. Dr. Tyna is also the host of The Dr. Tyna Show and an international speaker.What's Discussed:(08:48) How being “early” to the GLP-1 conversation led to backlash and burnout(10:49) How GLP-1 became misused and distorted by telemedicine and influencers(15:18) Why midlife weight gain isn't about willpower but a neurological shift(16:09) The idea of functional deficiency and why modern stress breaks signaling(19:15) How GLP-1 can increase motivation to move through brain plasticity(22:20) How GLP-1 can magnify existing hormonal deficiencies in women(24:11) Why movement is essential for gut health and metabolic signaling(28:01) Why microdosing is not a true weight loss strategy(35:44) Why strength training is non-negotiable for women in midlife(39:02) The real risks of frailty, hip fractures, and loss of independenceCheck out more from Broads:Website: www.broads.appInstagram: @broads.podcast @broads.appCheck out more from Tara LaFerrara:Website: www.taralaferrara.comInstagram: @taralaferraraYoutube: @TaraLaferraraTiktok: @taralaferraraCheck out more from Dr. Tyna, ND, DC:Website: www.drtyna.comInstagram: @drtynaYoutube: @drtyna

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00 Intro05:00 The Patrick Tuor Strategy06:36 The 10-Gram Cycle Myth10:42 Winning a Pro Card on Orals13:53 Engineering Degrees & Bodybuilding21:05 The Best Version of Justin (2016)26:23 Emergency Room Horror Stories28:19 Olympia Afterparties Exposed33:58 Samson Dauda & Travel Meals37:26 Genetics: Muscle Bellies & Skin Thickness38:53 The Pop-Tart Peak Week Disaster45:07 Dangers of Cookie Cutter Cycles47:25 The 1000mg Testosterone Standard50:21 Hyper-Responders vs. Hard Gainers55:40 The 20lb Rebound Phase59:34 Building a Freak Natural Base01:02:13 Failing Classes for Prep01:08:24 Bodybuilders in Bar Fights01:14:30 Old School "Factory" Protocols01:28:22 Insomnia & Dementia Risks01:32:19 Generic vs. Pharma GH01:36:47 18IU Insulin Pre-Workout01:41:56 IGF-1 for Massive Legs01:45:32 The Infection That Ruined Prep (C. Diff)01:51:34 Increlex: The Nuclear Option01:56:40 Underground vs. Pharmacy Gear Strength01:59:25 Halotestin Rage & High Blood Pressure02:07:53 Hair Loss: Thyroid vs. Gear02:14:21 Eating Bear Meat in Alaska02:20:35 The 3 Heart Tests You Need02:32:37 Peaking for the Texas Pro02:40:12 Q&A: High Dose Winstrol Loading?02:49:15 Training 30 Weeks With No Rest02:51:54 Perfect Insulin Timing02:55:37 Fixing the IFBB Pro League03:06:20 Conclusion & Life Advice

Peripheral artery disease has been called the ‘silent circulatory crisis'—affecting millions, limiting mobility, and quietly raising the risk of heart attack, stroke, and limb loss. For decades, treatment focused on walking programs, aspirin, and sometimes a stent or bypass. But today, the landscape is changing. From PCSK9 inhibitors that drive cholesterol to record lows, to GLP-1 agonists like semaglutide improving walking distance, to novel antithrombotic strategies that balance bleeding and clotting—PAD care is entering a new era. In this episode, we'll explore the breakthroughs, the evidence behind them, and what they mean for patients who just want to keep moving forward." Hosted by the University of Michigan Department of Vascular Surgery: - Robert Beaulieu, Program Director - Frank Davis, Assistant Professor of Surgery - Luciano Delbono, PGY-5 House Officer - Andrew Huang, PGY-4 House Officer - Carolyn Judge, PGY-2 House Officer Learning objectives:  1.  Describe the current evidence-based recommendations for multifactorial medical management of peripheral artery disease (PAD), including lipid, glycemic, and antithrombotic strategies per 2024 SVS/AHA guidelines.  2. Interpret the clinical implications of the FOURIER trial regarding the role of PCSK9 inhibition in reducing cardiovascular events in patients with atherosclerotic disease, including PAD.  3.  Evaluate the emerging role of GLP-1 receptor agonists, such as semaglutide, in improving walking performance and quality of life among patients with diabetic PAD based on findings from the STRIDE trial. Sponsor URL: https://www.goremedical.com/ References:  H. L. Gornik et al., “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease,” JACC, vol. 83, no. 24, pp. 2497–2604, June 2024, doi: 10.1016/j.jacc.2024.02.013. L. Mazzolai et al., “2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM),” Eur Heart J, vol. 45, no. 36, pp. 3538–3700, Sept. 2024, doi: 10.1093/eurheartj/ehae179. https://pubmed.ncbi.nlm.nih.gov/40169145/ M. S. Sabatine et al., “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease,” N Engl J Med, vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664. https://pubmed.ncbi.nlm.nih.gov/28304224/ M. P. Bonaca et al., “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial,” Lancet, vol. 405, no. 10489, pp. 1580–1593, May 2025, doi: 10.1016/S0140-6736(25)00509-4. https://pubmed.ncbi.nlm.nih.gov/40169145/ N. E. Hubbard, D. Lim, and K. L. Erickson, “Beef tallow increases the potency of conjugated linoleic acid in the reduction of mouse mammary tumor metastasis,” J Nutr, vol. 136, no. 1, pp. 88–93, Jan. 2006, doi: 10.1093/jn/136.1.88. https://pubmed.ncbi.nlm.nih.gov/16365064/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 Intro00:01:26 Holidays & Work00:02:14 Vegas vs. California: The "Realness" Factor00:03:00 The Secret to 23-Inch Arms00:04:57 Genetics: Korean Calves & Ethnic Muscle Insertions00:06:30 The New Generation of Bodybuilders00:08:27 The Boston Lloyd Controversy: Truth vs. Harm00:13:11 Debunking the "10 Grams of Gear" Myth00:14:53 Natural Bodybuilding & Social Media Expectations00:16:47 The Limitless Mindset00:18:52 Evan's Origin Story: From Obese to Anorexic00:20:39 The "Perma-Cut" Trap: Fear of Eating00:22:46 Drugs Are Tools, Not the Foundation00:25:42 Losing Gains to Stay Lean (The Teenage Mistake)00:28:03 Winning the First Show & Turning Pro00:28:27 Starting PEDs at Age 19 (500mg Test)00:30:51 First Cycle Results & The "Cold Turkey" PCT00:32:45 Coming Off Gear: Bloodwork Reality Check00:34:28 Rebound Strategies: Staying On vs. PCT00:36:58 Testing TRT Levels & Fertility00:39:53 Host Message: Subscribe & Sponsors00:41:03 First Growth Hormone Experience (Serostim)00:41:50 The Holy Trinity: Test, Tren, & Winstrol00:44:12 Injectable Winstrol: Alpha Pharma Rexogin00:46:26 Oral Winstrol Side Effects: Gut Health & Acne00:49:02 Quitting Orals (Reflux Issues)00:51:55 Modern Coaching Lunacy: High Dose Orals00:53:26 Acute Toxicity: Why Injectables are Safer00:58:09 Finding "Real" Injectable Winstrol 101:00:55 GH Strategies: Prep vs. Off-Season01:02:13 Insulin Without GH? The Joe Palacios Anomaly01:03:11 Is Growth Hormone Overrated?01:04:26 Cycling GH: 2 Days On, 1 Day Off01:05:21 The Ronnie Coleman Standard01:06:09 The GH15 Era & Internet Rumors01:09:42 The "One Bottle of Sustanon" Pre-Stage Protocol01:13:28 GH Frequency Debate01:16:19 What Pros Actually Take: The 4-6 IU Reality01:19:02 Steroids in Japan01:20:41 Earning the Pro Card01:21:10 2009 NY Pro Win & The Oscar Ardon Era01:23:58 Passion vs. Career: The Bodybuilder's Dilemma01:28:44 Evan's Heaviest Cycle: 1,500mg Test & Suspension01:30:55 The Cytadren (Aminoglutethimide) Nightmare 201:32:43 Diuretics & Dangerous Prep Protocols01:34:26 Insulin Frequency & Diabetes Risk01:37:53 Dangerous Modern Coaching: 100mg Orals Daily01:40:15 Longevity & The "One Vice" Rule01:43:45 Essentiale Forte: The Ultimate Liver Supplement 301:45:33 Host Message: Transcend HRT01:46:20 Training Philosophy: Oscar Ardon's "Mental Torture" 401:50:38 Science-Based Op

Welcome back to driving with Natalie! I decided it was too much fun to chat with you all in between the day to day so instead of posting a vault episode, let's hang out in my car again. So, my family and I got into some difficult conversations after the World Cup, Piper is now climbing out of her crib, and I am happy to share I am seeing some results from my semaglutide trial! Sponsor note: Go to ⁠Airdoctorpro.com⁠ and use promo code HUNGRY to get up to $300 off today.  Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, we're talking: Going no contact, All Her Fault, the Fanning Sisters, ADHD flow states, JVN's new favorite European city, Miss Universe pregnancy rules, Norway's royal family, Matthew Morrison's dance breaks, thirsty little c*nts on Tiktok, "rebranding" domestic terrorism, Bari Weiss, blocking CBS news, Glogg, Tumeric, and success with semaglutides.  Check out the JVN Patreon for exclusive content, bonus episodes, and more! www.patreon.com/jvn  Follow us on Instagram @gettingbetterwithjvn Jonathan on Instagram @jvn and senior producer Chris @amomentlikechris  New video episodes Getting Better on YouTube every Wednesday.  Senior Producer, Chris McClure Producer, Editor & Engineer is Nathanael McClure Production support from Chad Hall Our theme music is also composed by Nathanael McClure. Curious about bringing your brand to life on the show? Email podcastadsales@sonymusic.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices